Law360, New York (February 04, 2008, 12:00 AM ET) -- The bad news continues to pile up for Eli Lilly & Co., with the U.S. Food and Drug Administration issuing a word of caution about the excessive sedation connected to a long-form version of the company's popular schizophrenia drug Zyprexa.
On Monday, the FDA posted an analysis of Zyprexa Adhera, revealing a mixed bag regarding the effectiveness and potential side effects of the injectable formulation.
“FDA agrees that the sponsor has shown that Olanzapine Depot is effective in both the acute and maintenance treatment of schizophrenia,”...
FDA Uneasy About Long-Form Zyprexa Side Effect
To view the full article, take a free trial now.
